Vtama cream effective long-term for atopic dermatitis in adult, pediatric patients
Click Here to Manage Email Alerts
Key takeaways:
- 51.9% of patients achieved complete disease clearance at least once during the 48-week study.
- During the treatment-free interval, patients maintained disease clearance for an average of 79.8 days.
Dermavant Sciences presented full results from its long-term extension trial of Vtama cream 1% for the treatment of atopic dermatitis at the Fall Clinical Dermatology Conference, the company announced in a press release.
ADORING 3 is a phase 3, open-label, long-term extension study that evaluated the efficacy and safety of Vtama (tapinarof) cream 1% for the treatment of atopic dermatitis over the span of 48 weeks.
A total of 728 patients (83% aged 2 to 17 years) were enrolled in ADORING 3. According to the release, the study yielded promising results.
“In the ADORING long-term extension study, Vtama cream demonstrated a high rate of complete disease clearance,” Robert Bissonnette, MD, FRCPC, CEO at Innovaderm Research, said in the release. “Moreover, upon reaching complete disease clearance and ceasing treatment, patients stayed clear or almost clear for an average period of approximately 80 consecutive days.”
Complete disease clearance, as defined as a validated IGA (vIGA)-AD score of 0, was achieved at least once by 51.9% of patients during the span of the study. Almost clear skin, defined as a vIGA-AD score of 0 or 1, was achieved at least once by 81.6% of patients in the same time period.
Once complete disease clearance was reached, patients discontinued use of Vtama cream and achieved an average treatment-free interval of 79.8 consecutive days. Those who did experience a recurrence of mild or worse AD during this treatment-free course were able to reach complete clearance once retreated, according to the release.
During the 48-week study, none of the patients exhibited a loss of response to Vtama due to continuous treatment. According to the release, most treatment-emergent adverse events were mild to moderate, and the discontinuation rate remained low at 2.6%.